Silver Lake Advisory LLC Acquires 344 Shares of Bristol-Myers Squibb (NYSE:BMY)

Silver Lake Advisory LLC grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,350 shares of the biopharmaceutical company’s stock after buying an additional 344 shares during the quarter. Silver Lake Advisory LLC’s holdings in Bristol-Myers Squibb were worth $1,219,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of BMY. ESL Trust Services LLC bought a new position in Bristol-Myers Squibb during the 1st quarter worth approximately $27,000. LGT Financial Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 42.7% during the second quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 227 shares during the period. MFA Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb in the second quarter worth approximately $39,000. Fairman Group LLC purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $42,000. Finally, Beach Investment Counsel Inc. PA bought a new stake in Bristol-Myers Squibb during the 2nd quarter valued at $42,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

Shares of BMY opened at $50.91 on Friday. The firm’s 50-day simple moving average is $48.53 and its two-hundred day simple moving average is $46.33. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $58.46. The stock has a market cap of $103.20 billion, a PE ratio of -16.42, a price-to-earnings-growth ratio of 12.96 and a beta of 0.46. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The company had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. During the same quarter last year, the company earned $1.75 EPS. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. Analysts anticipate that Bristol-Myers Squibb will post 0.77 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 4.71%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on BMY. TD Cowen raised their price target on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft reduced their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Barclays boosted their target price on Bristol-Myers Squibb from $41.00 to $42.00 and gave the company an “underweight” rating in a research note on Thursday, August 22nd. Finally, BMO Capital Markets reaffirmed a “market perform” rating and issued a $48.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, September 23rd. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $55.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.